Furthermore, we confirmed the relationship between IKAROS and CD19 surface expression in LBCL (Supplementary Fig. 4A–C) and CLL (Supplementary Fig. 4D) models, suggesting that IKAROS modulation of CD19 surface expression is consistent across B cell malignancies. Here, IKZF1 is linked to B-cell chronic lymphocytic leukemia.